Professor Paulo Jordão criticizes high prices of analysis equipment for medicinal Cannabis
If the products were more affordable, it would be possible to analyze the exact compounds in the oils and offer a more effective treatment to patients
By Sechat Content
Paulo Jordão is a professor at the Federal University of Piauí and is responsible for leading studies on the analysis of cannabinoids and national genetics. He criticizes the high prices of Cannabis analysis equipment.
For him, being able to dose and isolate the compounds of the plant for the production of medications is essential because it allows for increased efficiency, as medical prescriptions can be made more specific to the patient. As the professor states, more affordable equipment such as thin-layer chromatography is capable of analyzing the exact compounds in imported oils, for example, and thus determining the best dosage for the treatment in question.
>>> Exclusive content from Sechat Lives is now even more accessible
These and other analyses on important topics involving the scenario of medicinal Cannabis in Brazil are in the Sechat Live, available on the Sechat YouTube channel and on the Instagram profile. The chat was broadcast live last week, on the 13th, with the guidance of the portal's partner and scientific director, neurosurgeon Pedro Antonio Pierro Neto.
According to Jordão, who is a founding partner of Cannapi, a company that manipulates Cannabis extracts, due to the high cost of these dosage and analysis equipment, it is necessary for the discussion on the creation of cheaper technologies to advance so that associations can have the conditions to have extraction equipment for further testing. For the entities, this would be essential to democratize research and information.
During the live, the professor also conducted a critical analysis of the substitute for Bill 399/2015, which is being processed in the Federal Chamber and aims to regulate the cultivation, processing, research, production, and commercialization of Cannabis-based products for medicinal and industrial purposes. According to him, even if delayed compared to other countries, it is important for the legislation to be approved. With the Judiciary allowing cultivation in some cases and ANVISA allowing the importation of medications and supplies, there will be a